Latigo Biotherapeutics Closes $150 Million in Series B Financing to Advance Non-Opioid Pain Therapeutics
Financing led by funds managed by Blue Owl Capital; Senior Managing Director Kevin Raidy joins Latigo’s board
Latigo Biotherapeutics Granted FDA Fast Track Designation for LTG-001, Potential Best-in-Class Nav1.8 Inhibitor for the Non-Opioid Treatment of Acute Pain
LTG-001 demonstrated favorable safety and tolerability profile with predictable pharmacokinetics in Phase 1 trial
Capsida Announces AbbVie Opt-in for First Genetic Medicine Program from Neurodegenerative Disease Collaboration
Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties
Borealis Biosciences Appoints Christian Hordo as CEO and Expands Series A Financing
Westlake BioPartners leads $30 million Series A extension, bringing the startup’s total committed capital to $180 million
New Preclinical Data Demonstrate Potential of Capsida’s IV Gene Therapy for STXBP1-DEE to Correct all Disease Manifestations
Data to be featured as oral and poster presentations at American Epilepsy Society 2024 Annual Meeting
Novartis has acquired Kate Therapeutics to further enhance and strengthen our ongoing efforts to advance gene therapies for patients.
Acquisition of Kate Therapeutics enhances and strengthens Novartis strategic priorities in gene therapy and neuroscience innovation
Latigo Biotherapeutics Appoints Industry Veteran Timothy P. Walbert as Board Chair
Former Horizon Therapeutics chairman & CEO brings 30 years of biopharmaceutical industry experience
Neuron23 Announces Usage of Roche’s Digital Biomarker and Device in Parkinson’s Disease Clinical Trial
Digital biomarker to enhance precision, reduce patient burden and boost efficiency of global Phase 2 trial of NEU-411 in early Parkinson’s disease
Neuron23 Unveils Groundbreaking Phase 2 Trial in Early Parkinson’s Disease
NEU-411, a brain-penetrant, potent and selective kinase inhibitor, has potential to slow disease progression in up to 30% of people with LRRK2-driven Parkinson’s disease
Capsida Biotherapeutics to Present New Preclinical Data for Potential Best-in-Class Friedreich’s Ataxia Next-Generation Gene Therapy
NHP data demonstrate potential for CAP-004 to treat CNS, cardiac, and sensory manifestations of Friedreich’s ataxia